The NSCI Therapeutics NewCo project aims at founding a for-profit regenerative medicine company. The pipeline is currently being developed as a not-for-profit organisation. The NewCo will aim at advancing cell-based therapies and biologics for retinal disease(s), e.g. dry AMD. The assets have been supported by already $21m in non-dilutive fundings; it is currently seeking $5m as seed funding to proceed early phase clinical trials (IND-ready).